The Synonymous Isocitrate Dehydrogenase 1 315C>T SNP Confers an Adverse Prognosis in Egyptian Adult Patients with NPM1-/CEBPA-Negative Acute Myeloid Leukemia
Although the clinical features of isocitrate dehydrogenase (IDH) genetic aberrations have been well-characterized in acute myeloid leukemia (AML), definitive information on their prognostic significance is lacking. We aimed to explore the prognostic significance of IDH gene alterations in an Egyptian cohort of adult patients with de novo AML. Diagnostic peripheral blood samples from 51 AML patients were analyzed for the presence of mutations/SNPs in exon 4 of IDH1 and IDH2 genes using polymerase chain reaction amplification followed by direct sequencing. IDH mutational status had no impact on event-free survival (EFS) and overall survival (OS), whereas the presence of IDH1 315C>T SNP was significantly associated with inferior EFS (P = 0.037) and OS (P = 0.034) as compared with wild-type IDH1. IDH1 315C>T SNP but not IDH mutations is associated with unfavorable outcomes, suggesting that AML patients with IDH1 315C>T SNP can represent a new subgroup of patients which allows refined risk stratification.
KeywordsAcute myeloid leukemia Isocitrate dehydrogenase 1 and 2 Mutations Single nucleotide polymorphisms Prognostic markers
Study conception and design: M.A.M.A. and R.H.; Patients recruitment and clinical monitoring: M.M.A.A.; Conducting the mutations analysis: M.A.M.A., E.K.A. and R.H.; acquisition of data: M.M.A.A. and R.H.; Analysis and interpretation of data: M.A.M.A.; Conceptualization and drafting of the manuscript: M.A.M.A.; Critical revision of the manuscript: M.A.M.A., E.K.A., M.M.A.A. and R.H.; All authors have approved the final version of the submitted manuscript. All authors have contributed significantly to this study, and all of them are in agreement with the content of the manuscript.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the National Cancer Institute research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 11.Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D et al (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia Group B study. J Clin Oncol 28:2348–2355CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Virijevic M, Karan-Djurasevic T, Marjanovic I, Tosic N, Mitrovic M, Djunic I et al (2016) Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype. Radiol Oncol 50:385–393CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T (2010) IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 116:5486–5496CrossRefPubMedGoogle Scholar